Recent studies have focused on the overlap of GLP-1|glucose-dependent insulinotropic polypeptide|glucagon receptor agonist therapies and dopaminergic neurotransmission. While GCGR activators are increasingly employed for addressing type 2 T2DM, their emerging consequences on motivation circuits, specifically mediated by dopamine pathways, are recei